Merrimack Pharmaceuticals... (MACK)
NASDAQ: MACK
· Real-Time Price · USD
15.14
0.01 (0.07%)
At close: May 17, 2024, 7:59 PM
Company Description
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company.
The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Merrimack Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Mar 29, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 0 |
| CEO | Gary L. Crocker M.B.A. |
Contact Details
Address: One Broadway Cambridge, Massachusetts United States | |
| Website | https://www.merrimack.com |
Stock Details
| Ticker Symbol | MACK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001274792 |
| CUSIP Number | 590328209 |
| ISIN Number | US5903282094 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gary L. Crocker M.B.A. | President, Treasurer, Principal Financial Officer, Principal Accounting Officer, Chief Executive Officer & Chairman |
| Dr. Anthony J. Sinskey Ph.D., Sc.D. | Co-Founder and Scientific Advisor |
| Dr. Ulrik B. Nielsen Ph.D. | Co-Founder & Independent Director |
| Timothy R. Surgenor | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 20, 2024 | 15-12G | Filing |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | 25 | Filing |
| May 10, 2024 | 8-K | Current Report |
| May 09, 2024 | DEFA14A | Filing |
| May 09, 2024 | 8-K | Current Report |
| Apr 30, 2024 | DEFA14A | Filing |
| Apr 30, 2024 | 8-K | Current Report |
| Apr 01, 2024 | DEFR14A | Filing |
| Mar 27, 2024 | DEFA14A | Filing |